First quarter with 2% growth in Swiss francs, 7% at constant exchange rates

Group sales increase 2% in Swiss francs and 7% at constant exchange rates, driven by new products, more than compensating for impact of competition from biosimilars Pharmaceuticals Division sales up 7%, led by Tecentriq, Hemlibra, Ocrevus and Perjeta Diagnostics Division sales grow 5%, with molecular testing as main contributor
Source: Roche Media News - Category: Pharmaceuticals Source Type: news